TDMS Study 96022-02 Pathology Tables
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
FINAL# RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFPCBMIX
Lock Date: 11/04/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 86 98 86
Early Deaths
Moribund Sacrifice 21 20 21 23 43 44
Natural Death 5 14 8 13 10 22
Dosing Accident 2
Survivors
Terminal Sacrifice 27 17 24 15
Animals Examined Microscopically 53 51 53 53 53 66
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (51) (53) (53) (53) (66)
Degeneration 1 (2%)
Muscularis, Inflammation 3 (6%) 2 (4%) 3 (6%) 3 (6%) 2 (3%)
Intestine Large, Colon (53) (51) (53) (53) (52) (65)
Parasite Metazoan 2 (4%) 1 (2%) 2 (3%)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%)
Intestine Large, Rectum (52) (51) (53) (53) (52) (66)
Hyperplasia, Cystic 1 (2%)
Parasite Metazoan 3 (6%) 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 3 (6%) 1 (2%)
Intestine Large, Cecum (53) (51) (53) (53) (52) (65)
Edema 2 (3%)
Inflammation 2 (3%)
Artery, Inflammation, Chronic Active 2 (4%)
Intestine Small, Duodenum (53) (51) (53) (53) (53) (65)
Dilatation 1 (2%)
Erosion 1 (2%)
Hyperplasia 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Intestine Small, Ileum (53) (51) (53) (53) (52) (65)
Parasite Metazoan 1 (2%)
Liver (53) (51) (53) (53) (53) (65)
Angiectasis 1 (2%) 2 (4%) 1 (2%) 3 (6%) 2 (3%)
Basophilic Focus 14 (26%) 8 (16%) 6 (11%) 5 (9%) 4 (8%)
Basophilic Focus, Multiple 13 (25%) 8 (16%) 4 (8%) 3 (6%)
Cholangiofibrosis 1 (2%) 2 (4%) 3 (6%) 21 (40%) 42 (79%) 29 (45%)
Clear Cell Focus 4 (8%) 1 (2%)
Clear Cell Focus, Multiple 1 (2%) 1 (2%)
Degeneration, Cystic 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Eosinophilic Focus 5 (9%) 5 (10%) 11 (21%) 1 (2%) 2 (4%)
Eosinophilic Focus, Multiple 5 (9%) 16 (31%) 12 (23%) 14 (26%) 4 (8%) 10 (15%)
Fatty Change, Diffuse 3 (6%) 14 (27%) 27 (51%) 45 (85%) 49 (92%) 56 (86%)
Fatty Change, Focal 10 (19%) 10 (20%) 6 (11%) 1 (2%) 10 (19%) 6 (9%)
Hematopoietic Cell Proliferation 27 (51%) 27 (53%) 30 (57%) 32 (60%) 22 (42%) 11 (17%)
Hepatodiaphragmatic Nodule 2 (4%) 2 (4%) 2 (4%)
Hyperplasia, Nodular 10 (19%) 45 (85%) 50 (94%) 61 (94%)
Inflammation 49 (92%) 47 (92%) 50 (94%) 52 (98%) 51 (96%) 64 (98%)
Metaplasia 4 (8%) 4 (6%)
Mineralization 1 (2%)
Mixed Cell Focus 5 (9%) 5 (10%) 4 (8%) 1 (2%) 3 (5%)
Mixed Cell Focus, Multiple 33 (62%) 23 (45%) 28 (53%) 16 (30%) 1 (2%)
Necrosis 3 (6%) 13 (25%) 6 (11%) 26 (49%) 17 (32%) 27 (42%)
Pigmentation 5 (9%) 18 (35%) 38 (72%) 52 (98%) 53 (100%) 60 (92%)
Thrombosis 1 (2%)
Toxic Hepatopathy 8 (16%) 32 (60%) 51 (96%) 52 (98%) 64 (98%)
Artery, Inflammation 1 (2%) 1 (2%)
Bile Duct, Cyst 4 (8%) 3 (6%) 3 (6%) 14 (26%) 25 (47%) 14 (22%)
Bile Duct, Dilatation 1 (2%)
Bile Duct, Fibrosis 6 (11%) 2 (4%) 3 (6%) 10 (19%) 3 (6%) 4 (6%)
Bile Duct, Hyperplasia 5 (9%) 5 (10%) 7 (13%) 46 (87%) 52 (98%) 60 (92%)
Centrilobular, Degeneration 2 (4%) 3 (6%) 8 (15%) 8 (15%) 3 (6%) 8 (12%)
Centrilobular, Fibrosis 7 (13%) 36 (68%) 52 (98%) 57 (88%)
Hepatocyte, Glandular Structures 1 (2%) 5 (9%) 25 (38%)
Hepatocyte, Hypertrophy 16 (31%) 22 (42%) 47 (89%) 52 (98%) 65 (100%)
Hepatocyte, Multinucleated 9 (18%) 21 (40%) 48 (91%) 52 (98%) 48 (74%)
Oval Cell, Hyperplasia 4 (8%) 4 (8%) 23 (43%) 49 (92%) 52 (98%) 62 (95%)
Portal, Fibrosis 2 (4%) 37 (70%) 52 (98%) 58 (89%)
Serosa, Inflammation 2 (4%)
Mesentery (53) (35) (45) (49) (52) (63)
Inflammation 1 (3%)
Necrosis 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (3%) 1 (2%) 9 (18%) 9 (17%) 3 (5%)
Fat, Necrosis 1 (2%) 3 (6%) 3 (5%)
Oral Mucosa (53) (51) (53) (53) (53) (66)
Cyst 1 (2%)
Gingival, Hyperplasia, Squamous 11 (21%) 10 (20%) 20 (38%) 24 (45%) 27 (51%) 18 (27%)
Pancreas (53) (51) (53) (53) (53) (65)
Edema 1 (2%) 4 (8%) 19 (29%)
Hemorrhage 2 (3%)
Inflammation, Chronic Active 1 (2%) 5 (10%) 4 (8%) 3 (6%) 2 (4%) 6 (9%)
Lipomatosis 1 (2%) 1 (2%)
Acinus, Atrophy 1 (2%) 5 (10%) 3 (6%) 5 (9%) 9 (17%) 8 (12%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Acinus, Hyperplasia 2 (4%)
Acinus, Hyperplasia, Focal 1 (2%)
Acinus, Vacuolization Cytoplasmic 1 (2%) 8 (15%) 39 (74%) 49 (92%) 43 (66%)
Artery, Inflammation, Chronic Active 2 (4%) 2 (4%) 21 (40%) 14 (26%) 4 (6%)
Duct, Dilatation 1 (2%) 3 (6%)
Salivary Glands (53) (51) (53) (52) (52) (66)
Atrophy 1 (2%)
Stomach, Forestomach (53) (51) (53) (53) (53) (65)
Edema 2 (4%) 1 (2%)
Erosion 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Squamous 4 (8%) 1 (2%) 3 (6%) 11 (21%) 4 (8%) 9 (14%)
Inflammation 2 (4%) 2 (4%) 4 (8%) 1 (2%)
Mineralization 1 (2%) 2 (3%)
Ulcer 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 2 (4%)
Stomach, Glandular (53) (51) (53) (53) (53) (65)
Cyst 1 (2%)
Erosion 1 (2%) 1 (2%) 2 (3%)
Hemorrhage 1 (2%) 3 (5%)
Inflammation 1 (2%)
Mineralization 12 (23%) 6 (12%) 6 (11%) 1 (2%) 6 (11%) 5 (8%)
Glands, Cyst 1 (2%)
Tongue (1)
Cyst 1 (100%)
Tooth (29) (26) (33) (34) (29) (25)
Peridontal Tissue, Inflammation 29 (100%) 26 (100%) 33 (100%) 34 (100%) 29 (100%) 25 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (51) (52) (53) (53) (66)
Mineralization 1 (2%)
Aorta, Adventitia, Hemorrhage 1 (2%) 1 (2%)
Aorta, Adventitia, Inflammation 1 (2%) 2 (3%)
Heart (53) (51) (53) (53) (53) (65)
Cardiomyopathy 20 (38%) 13 (25%) 17 (32%) 34 (64%) 14 (26%) 19 (29%)
Atrium, Thrombosis 1 (2%)
Coronary Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 7 (13%) 10 (19%) 9 (14%)
Coronary Artery, Thrombosis 1 (2%)
Endocardium, Hyperplasia 1 (2%)
Epicardium, Hemorrhage 1 (2%)
Epicardium, Inflammation 1 (2%) 1 (2%) 6 (11%) 13 (25%) 6 (9%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Myocardium, Hemorrhage 3 (5%)
Myocardium, Inflammation 1 (2%)
Myocardium, Necrosis 2 (3%)
Pericardium, Inflammation, Chronic Active 1 (2%)
Valve, Fibrosis 1 (2%)
Valve, Hyperplasia 1 (2%)
Ventricle, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (51) (53) (53) (53) (65)
Angiectasis 42 (79%) 35 (69%) 39 (74%) 25 (47%) 4 (8%) 6 (9%)
Atrophy 2 (4%) 1 (2%) 15 (28%) 44 (83%) 40 (62%)
Degeneration, Cystic 12 (23%) 12 (24%) 13 (25%) 11 (21%) 6 (11%) 2 (3%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 13 (25%) 7 (14%) 13 (25%) 12 (23%) 10 (19%) 5 (8%)
Hypertrophy 45 (85%) 40 (78%) 47 (89%) 44 (83%) 45 (85%) 27 (42%)
Inflammation 1 (2%)
Necrosis 1 (2%) 2 (4%) 4 (8%) 1 (2%) 4 (6%)
Vacuolization Cytoplasmic 14 (26%) 16 (31%) 13 (25%) 24 (45%) 27 (51%) 12 (18%)
Adrenal Medulla (53) (51) (53) (53) (53) (64)
Hyperplasia 13 (25%) 4 (8%) 9 (17%) 12 (23%) 2 (4%)
Islets, Pancreatic (53) (51) (53) (53) (53) (65)
Hyperplasia 1 (2%)
Pituitary Gland (53) (51) (52) (53) (53) (65)
Angiectasis 23 (43%) 13 (25%) 19 (37%) 7 (13%)
Cyst 1 (2%)
Cytoplasmic Alteration 1 (2%) 1 (2%)
Necrosis 1 (2%)
Vacuolization Cytoplasmic 2 (4%) 1 (2%) 5 (9%)
Pars Distalis, Hyperplasia 11 (21%) 14 (27%) 19 (37%) 18 (34%) 4 (8%) 1 (2%)
Thyroid Gland (53) (51) (53) (52) (52) (66)
Hemorrhage 1 (2%)
Inflammation 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
C-Cell, Hyperplasia 7 (13%) 11 (22%) 13 (25%) 10 (19%) 15 (29%) 3 (5%)
Follicle, Cyst 1 (2%)
Follicular Cell, Hyperplasia 2 (4%) 1 (2%)
Follicular Cell, Hypertrophy 22 (42%) 35 (69%) 34 (64%) 38 (73%) 44 (85%) 37 (56%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (51) (51) (52) (52) (66)
Inflammation 49 (92%) 44 (86%) 46 (90%) 34 (65%) 21 (40%) 31 (47%)
Artery, Inflammation, Chronic Active 1 (2%)
Duct, Cyst 40 (75%) 41 (80%) 43 (84%) 45 (87%) 48 (92%) 61 (92%)
Ovary (53) (51) (53) (53) (53) (65)
Atrophy 46 (87%) 34 (67%) 43 (81%) 42 (79%) 7 (13%) 9 (14%)
Cyst 19 (36%) 12 (24%) 15 (28%) 19 (36%) 8 (15%) 13 (20%)
Inflammation 3 (6%) 3 (6%)
Inflammation, Chronic Active 1 (2%) 3 (6%) 3 (6%)
Artery, Inflammation 1 (2%)
Periovarian Tissue, Inflammation, Chronic
Active 1 (2%)
Oviduct (1)
Cyst 1 (100%)
Inflammation 1 (100%)
Uterus (53) (51) (53) (53) (53) (66)
Adenomyosis 1 (2%) 3 (6%) 1 (2%)
Congestion 1 (2%)
Hemorrhage 2 (4%) 1 (2%)
Hyperplasia, Cystic 1 (2%)
Inflammation, Chronic Active 2 (4%) 5 (10%) 2 (4%) 5 (9%)
Inflammation, Suppurative 4 (8%) 3 (6%) 5 (9%) 7 (13%) 2 (3%)
Metaplasia, Squamous 23 (43%) 24 (47%) 28 (53%) 24 (45%)
Thrombosis 1 (2%)
Endometrium, Hyperplasia, Cystic 32 (60%) 23 (45%) 25 (47%) 30 (57%) 7 (13%) 8 (12%)
Serosa, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (51) (53) (53) (53) (66)
Atrophy 2 (4%) 12 (18%)
Hyperplasia 37 (70%) 41 (80%) 36 (68%) 48 (91%) 47 (89%) 49 (74%)
Lymph Node (28) (16) (16) (25) (20) (45)
Hemorrhage 1 (4%)
Deep Cervical, Congestion 1 (4%)
Deep Cervical, Ectasia 1 (4%)
Deep Cervical, Hemorrhage 1 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Deep Cervical, Hyperplasia, Histiocytic 1 (4%)
Deep Cervical, Hyperplasia, Plasma Cell 1 (4%)
Lumbar, Ectasia 1 (6%) 1 (4%)
Lumbar, Hemorrhage 1 (4%)
Lumbar, Hyperplasia, Plasma Cell 1 (6%)
Mediastinal, Congestion 1 (4%)
Mediastinal, Ectasia 7 (25%) 7 (44%) 7 (44%) 7 (28%) 7 (35%) 27 (60%)
Mediastinal, Hemorrhage 2 (7%) 2 (13%) 4 (25%) 15 (60%) 7 (35%) 25 (56%)
Mediastinal, Hyperplasia, Histiocytic 2 (8%) 2 (10%) 2 (4%)
Mediastinal, Hyperplasia, Lymphoid 2 (13%)
Mediastinal, Hyperplasia, Plasma Cell 3 (19%) 1 (4%)
Mediastinal, Pigmentation 2 (4%)
Pancreatic, Ectasia 1 (5%) 1 (2%)
Pancreatic, Hemorrhage 1 (5%) 4 (9%)
Pancreatic, Hyperplasia, Histiocytic 1 (4%) 4 (20%) 3 (7%)
Pancreatic, Hyperplasia, Lymphoid 2 (8%) 1 (2%)
Renal, Ectasia 1 (6%) 1 (4%) 1 (5%)
Renal, Hemorrhage 1 (5%)
Renal, Hyperplasia 1 (5%)
Renal, Hyperplasia, Histiocytic 1 (5%) 2 (4%)
Lymph Node, Mandibular (53) (51) (53) (52) (52) (66)
Atrophy 1 (2%)
Ectasia 3 (6%) 2 (4%) 3 (6%) 4 (8%) 4 (8%) 1 (2%)
Hemorrhage 1 (2%) 2 (4%) 7 (11%)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 3 (6%) 2 (4%) 1 (2%)
Hyperplasia, Plasma Cell 45 (85%) 35 (69%) 34 (64%) 27 (52%) 22 (42%) 20 (30%)
Necrosis 1 (2%)
Necrosis, Lymphoid 1 (2%)
Pigmentation 1 (2%)
Lymph Node, Mesenteric (53) (51) (53) (53) (52) (65)
Ectasia 1 (2%) 1 (2%) 2 (4%) 1 (2%) 2 (3%)
Hemorrhage 2 (4%) 2 (4%) 2 (4%) 4 (8%) 14 (22%)
Hyperplasia, Histiocytic 2 (4%) 1 (2%) 6 (11%) 5 (10%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Hyperplasia, Plasma Cell 1 (2%)
Spleen (53) (51) (53) (53) (53) (65)
Hematopoietic Cell Proliferation 49 (92%) 44 (86%) 49 (92%) 52 (98%) 50 (94%) 43 (66%)
Pigmentation 52 (98%) 50 (98%) 52 (98%) 50 (94%) 50 (94%) 59 (91%)
Artery, Inflammation, Chronic Active 1 (2%)
Capsule, Fibrosis 1 (2%)
Lymphoid Follicle, Atrophy 4 (8%) 5 (10%) 2 (4%) 5 (9%) 3 (6%) 9 (14%)
Red Pulp, Atrophy 1 (2%) 2 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Thymus (53) (51) (51) (51) (51) (59)
Atrophy 40 (75%) 44 (86%) 44 (86%) 49 (96%) 50 (98%) 57 (97%)
Hemorrhage 2 (4%)
Necrosis 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (51) (53) (53) (53) (66)
Cyst 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Hyperplasia 26 (49%) 17 (33%) 13 (25%) 6 (11%) 6 (11%)
Inflammation 1 (2%)
Inflammation, Granulomatous 3 (6%) 2 (4%) 1 (2%)
Skin (53) (51) (53) (53) (53) (66)
Cyst Epithelial Inclusion 1 (2%) 2 (4%) 1 (2%)
Hemorrhage 1 (2%)
Inflammation 1 (2%) 1 (2%)
Ulcer 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic
Active 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (51) (53) (53) (53) (66)
Hemorrhage 1 (2%) 1 (2%) 4 (8%) 5 (9%) 14 (21%)
Hydrocephalus 1 (2%)
Inflammation 2 (4%) 1 (2%)
Mineralization 1 (2%)
Necrosis 2 (4%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Cerebrum, Degeneration 1 (2%)
Meninges, Inflammation 1 (2%)
Meninges, Vein, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (51) (53) (53) (53) (66)
Congestion 2 (4%)
Hemorrhage 1 (2%) 2 (4%) 4 (6%)
Infiltration Cellular, Histiocyte 40 (75%) 33 (65%) 46 (87%) 48 (91%) 46 (87%) 33 (50%)
Inflammation 5 (9%) 9 (18%) 7 (13%) 3 (6%) 2 (4%) 2 (3%)
Metaplasia, Squamous 1 (2%) 2 (4%) 14 (26%) 16 (30%) 7 (11%)
Necrosis 1 (2%)
Alveolar Epithelium, Hyperplasia 18 (34%) 10 (20%) 2 (4%) 1 (2%) 1 (2%) 4 (6%)
Alveolar Epithelium, Metaplasia, Bronchiolar 1 (2%) 14 (27%) 39 (74%) 46 (87%) 35 (66%) 8 (12%)
Artery, Thrombosis 1 (2%)
Artery, Mediastinum, Inflammation, Chronic
Active 1 (2%)
Mediastinum, Inflammation 1 (2%)
Serosa, Fibrosis 3 (6%) 1 (2%) 16 (30%) 8 (12%)
Nose (53) (51) (53) (53) (53) (66)
Inflammation 17 (32%) 15 (29%) 16 (30%) 10 (19%) 22 (42%) 11 (17%)
Necrosis 1 (2%)
Ulcer 1 (2%)
Glands, Hyperplasia 2 (4%)
Olfactory Epithelium, Degeneration 1 (2%)
Olfactory Epithelium, Metaplasia 2 (4%) 1 (2%) 3 (6%) 8 (15%) 1 (2%)
Respiratory Epithelium, Hyperplasia 8 (15%) 11 (22%) 5 (9%) 8 (15%) 16 (30%) 9 (14%)
Squamous Epithelium, Hyperplasia 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (51) (53) (53) (53) (66)
Cataract 1 (2%) 3 (6%)
Cornea, Inflammation 1 (2%) 1 (2%) 1 (2%)
Iris, Inflammation 1 (2%)
Retina, Atrophy 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Retina, Degeneration 1 (2%)
Harderian Gland (53) (51) (53) (53) (53) (66)
Inflammation 24 (45%) 7 (14%) 20 (38%) 13 (25%) 7 (13%) 9 (14%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (51) (53) (53) (53) (65)
Calculus Micro Observation Only 6 (11%) 6 (12%) 6 (11%)
Cyst 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/
0 UG 10 UG 30 UG 100 UG 300 UG 500 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Infarct 2 (4%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Inflammation, Suppurative 1 (2%) 4 (8%) 3 (6%) 1 (2%)
Mineralization 46 (87%) 34 (67%) 38 (72%) 44 (83%) 34 (64%) 37 (57%)
Necrosis 1 (2%)
Nephropathy 41 (77%) 37 (73%) 37 (70%) 48 (91%) 50 (94%) 43 (66%)
Pigmentation 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Pelvis, Dilatation 1 (2%)
Pelvis, Inflammation 4 (8%) 6 (12%) 1 (2%) 6 (11%)
Renal Tubule, Hyperplasia 2 (4%)
Transitional Epithelium, Hyperplasia 4 (8%) 6 (12%) 6 (11%) 16 (30%) 1 (2%)
Transitional Epithelium, Metaplasia, Squamous 1 (2%)
Ureter (1)
Transitional Epithelium, Hyperplasia 1 (100%)
Urinary Bladder (53) (51) (53) (53) (52) (66)
Calculus Gross Observation 1 (2%)
Edema 1 (2%)
Inflammation 8 (15%) 3 (6%) 2 (4%) 4 (8%) 1 (2%)
Metaplasia, Squamous 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Transitional Epithelium, Hyperplasia 4 (8%) 2 (4%) 4 (8%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50
Early Deaths
Moribund Sacrifice 28
Natural Death 12
Survivors
Terminal Sacrifice 10
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50)
Parasite Metazoan 1 (2%)
Intestine Large, Rectum (50)
Parasite Metazoan 1 (2%)
Artery, Inflammation, Chronic Active 4 (8%)
Intestine Large, Cecum (50)
Edema 1 (2%)
Inflammation 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Intestine Small, Ileum (50)
Parasite Metazoan 1 (2%)
Liver (50)
Angiectasis 4 (8%)
Basophilic Focus 2 (4%)
Basophilic Focus, Multiple 3 (6%)
Cholangiofibrosis 27 (54%)
Clear Cell Focus 1 (2%)
Degeneration, Cystic 1 (2%)
Eosinophilic Focus 1 (2%)
Eosinophilic Focus, Multiple 14 (28%)
Fatty Change, Diffuse 35 (70%)
Fatty Change, Focal 14 (28%)
Hematopoietic Cell Proliferation 22 (44%)
Hemorrhage 1 (2%)
Hepatodiaphragmatic Nodule 1 (2%)
Hyperplasia, Nodular 34 (68%)
Inflammation 48 (96%)
Metaplasia 2 (4%)
Mixed Cell Focus 1 (2%)
Mixed Cell Focus, Multiple 19 (38%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Necrosis 6 (12%)
Pigmentation 50 (100%)
Toxic Hepatopathy 50 (100%)
Bile Duct, Cyst 21 (42%)
Bile Duct, Fibrosis 12 (24%)
Bile Duct, Hyperplasia 37 (74%)
Centrilobular, Degeneration 6 (12%)
Centrilobular, Fibrosis 43 (86%)
Hepatocyte, Glandular Structures 9 (18%)
Hepatocyte, Hypertrophy 36 (72%)
Hepatocyte, Multinucleated 38 (76%)
Oval Cell, Hyperplasia 43 (86%)
Portal, Fibrosis 42 (84%)
Serosa, Fibrosis 1 (2%)
Mesentery (43)
Necrosis 1 (2%)
Artery, Inflammation, Chronic Active 7 (16%)
Oral Mucosa (50)
Gingival, Hyperplasia, Squamous 18 (36%)
Pancreas (50)
Edema 12 (24%)
Hemorrhage 1 (2%)
Inflammation, Chronic Active 5 (10%)
Acinus, Atrophy 8 (16%)
Acinus, Vacuolization Cytoplasmic 41 (82%)
Artery, Inflammation, Chronic Active 10 (20%)
Stomach, Forestomach (50)
Edema 1 (2%)
Hyperplasia, Squamous 2 (4%)
Inflammation 2 (4%)
Mineralization 1 (2%)
Ulcer 2 (4%)
Stomach, Glandular (50)
Mineralization 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Tooth (23)
Peridontal Tissue, Inflammation 23 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50)
Aorta, Adventitia, Hemorrhage 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Aorta, Adventitia, Inflammation 2 (4%)
Heart (50)
Cardiomyopathy 15 (30%)
Atrium, Thrombosis 1 (2%)
Coronary Artery, Inflammation, Chronic Active 6 (12%)
Epicardium, Inflammation 1 (2%)
Myocardium, Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50)
Angiectasis 21 (42%)
Atrophy 12 (24%)
Degeneration, Cystic 9 (18%)
Hyperplasia 10 (20%)
Hypertrophy 29 (58%)
Inflammation 2 (4%)
Necrosis 2 (4%)
Vacuolization Cytoplasmic 16 (32%)
Adrenal Medulla (49)
Hyperplasia 8 (16%)
Pituitary Gland (50)
Angiectasis 3 (6%)
Cyst 3 (6%)
Cytoplasmic Alteration 2 (4%)
Pars Distalis, Hyperplasia 8 (16%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (49)
Infiltration Cellular, Lymphoid 2 (4%)
C-Cell, Hyperplasia 6 (12%)
Follicular Cell, Hypertrophy 29 (59%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50)
Inflammation 30 (60%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Duct, Cyst 40 (80%)
Ovary (50)
Atrophy 15 (30%)
Cyst 7 (14%)
Uterus (50)
Congestion 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic Active 1 (2%)
Inflammation, Suppurative 4 (8%)
Metaplasia, Squamous 8 (16%)
Cervix, Stromal Hyperplasia 1 (2%)
Endometrium, Hyperplasia, Cystic 17 (34%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50)
Atrophy 4 (8%)
Hyperplasia 40 (80%)
Lymph Node (22)
Lumbar, Hemorrhage 1 (5%)
Lumbar, Hyperplasia, Histiocytic 1 (5%)
Mediastinal, Ectasia 3 (14%)
Mediastinal, Hemorrhage 11 (50%)
Mediastinal, Hyperplasia, Histiocytic 4 (18%)
Mediastinal, Hyperplasia, Lymphoid 1 (5%)
Mediastinal, Hyperplasia, Plasma Cell 1 (5%)
Pancreatic, Hemorrhage 3 (14%)
Pancreatic, Hyperplasia, Histiocytic 3 (14%)
Pancreatic, Hyperplasia, Lymphoid 1 (5%)
Renal, Ectasia 1 (5%)
Renal, Hemorrhage 2 (9%)
Renal, Hyperplasia, Histiocytic 3 (14%)
Lymph Node, Mandibular (49)
Ectasia 11 (22%)
Hemorrhage 4 (8%)
Hyperplasia, Plasma Cell 28 (57%)
Inflammation 1 (2%)
Lymph Node, Mesenteric (50)
Ectasia 1 (2%)
Hemorrhage 10 (20%)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Plasma Cell 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Spleen (50)
Hematopoietic Cell Proliferation 45 (90%)
Pigmentation 41 (82%)
Lymphoid Follicle, Atrophy 4 (8%)
Thymus (46)
Atrophy 45 (98%)
Hemorrhage 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Cyst 1 (2%)
Hyperplasia 11 (22%)
Inflammation, Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50)
Tarsal, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50)
Hemorrhage 8 (16%)
Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Hemorrhage 3 (6%)
Infiltration Cellular, Histiocyte 24 (48%)
Inflammation 6 (12%)
Inflammation, Granulomatous 4 (8%)
Keratin Cyst 9 (18%)
Metaplasia, Squamous 8 (16%)
Alveolar Epithelium, Hyperplasia 5 (10%)
Alveolar Epithelium, Metaplasia, Bronchiolar 15 (30%)
Serosa, Fibrosis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 15
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Date: 04/29/04
Route: GAVAGE Time: 08:06:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 4000 NG/
500UG ST
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Nose (50)
Inflammation 11 (22%)
Olfactory Epithelium, Metaplasia 5 (10%)
Respiratory Epithelium, Hyperplasia 10 (20%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50)
Retina, Atrophy 1 (2%)
Harderian Gland (50)
Inflammation 12 (24%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Accumulation, Hyaline Droplet 1 (2%)
Cyst 1 (2%)
Mineralization 32 (64%)
Nephropathy 34 (68%)
Urinary Bladder (50)
Inflammation 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 16
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------